Jeremy L. Wally, CDR, PhD

FDA/CBER/OCBQ/DIS
Acting Chief, Program Surveillance Branch
CDR Jeremy Wally is the Chief of the Program Surveillance Branch, within the Division of Inspections and Surveillance, Office of Compliance and Product Quality, Center for Biologics Evaluation and Review, at the US Food and Drug Administration. Prior to joining the Program Surveillance Branch in 2017 on detail, CDR Wally served as a reviewer and inspector within the Division of Manufacturing and Product Quality since September 2013, where he performed details as the Acting Branch Chief and Acting Team Leader of the Manufacturing Review Branch 2. Previously, CDR Wally served for six years as a primary reviewer in the Office of Vaccines Research and Review where he focused on project management and the review of investigational and licensed vaccines.

CDR Wally holds a PhD in Biophysics and MA in Biochemistry from Boston University School of Medicine, a BA in Biology from Brandeis University, a Project Management Professional certification from the Project Management Institute, a Certified Quality Process Analyst certification from the American Society of Quality, and is Certified in Public Health by the National Board of Public Health Examiners. After completing his doctorate degree, CDR Wally completed a three-year post-doctorate fellowship in the Laboratory of Molecular Biology at the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health.

CDR Wally was commissioned as a US Public Health Service Commissioned Corps Officer in 2008, and has deployed in support and leadership roles for the responses to Hurricanes Irma, Maria and Sandy, and for the Unaccompanied Children mission.